Reta (Retatrutide)
GLP-1 / GIP / Glucagon Triple Agonist
4.8 (312)
$39.99
In stock
Professional use only · Investigational drug. Not tirzepatide. Not approved for human use outside trials.
Research grade
Trusted brand
Purity tested
Refrigerate 2–8°C
What It Is
Retatrutide is an investigational triple agonist of the GLP-1, GIP and glucagon receptors, in phase 3 trials for obesity. It is a different compound from tirzepatide (a dual GLP-1/GIP agonist) and is not approved for any use.
Key Benefits
- Phase 2 trials showed substantial weight reduction
- Reduces appetite via GLP-1 receptor activity
- Glucagon activity may increase energy expenditure
- Being studied for type 2 diabetes and fatty liver
- Once-weekly dosing in clinical trials
- Long-term safety data not yet available
Common Goals
Treatment suitability and placement require qualified clinical assessment.
How It Works
Retatrutide activates GLP-1, GIP and glucagon receptors. GLP-1 and GIP signalling reduce appetite and improve glycaemic control, while glucagon receptor activity is thought to increase energy expenditure. Efficacy and safety are still being established in phase 3 trials.
Treatment Overview
AdministrationSubcutaneous (clinical trials)
FrequencyOnce weekly in trials
ResultsInvestigational
Side effectsGI effects, raised heart rate
StorageRefrigerate 2–8°C
ProviderResearch / clinical trial setting
Safety & Professional Use
Common effectsNausea, vomiting, diarrhoea, constipation
Possible risksPancreatitis, gallbladder disease, arrhythmia
ContraindicationsMTC/MEN2 history, pregnancy, pancreatitis
StatusInvestigational; not FDA approved
These are general guidelines. Dosing and placement are determined by the treating clinician based on anatomy, indication and product labelling. Investigational drug. Not tirzepatide. Not approved for human use outside trials.
